• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Weight loss: 1st commercial implant of EnteroMedics’ Maestro device

Weight loss: 1st commercial implant of EnteroMedics’ Maestro device

May 21, 2015 By Fink Densford

EnteroMedics announces 1st commercial implant of Maestro weight loss device

EnteroMedics (NSDQ:ETRM) said today that the first commercial patient has been implanted with its Maestro neurostimulation anti-obesity implant.

The surgery took place at Tufts Medical Center in Boston May 13, performed by Dr. Sajani Shah, EnteroMedics said.

The Maestro is designed to use what EnteroMedics calls "vBloc therapy" in which electrical pulses are used to block intra-abdominal vagus nerve signaling between the brain and stomach using a pacemaker-like device, the company said.

“Until recently, there was a great unmet need for new, alternative treatment options for obese patients for whom behavior modification, pharmaceutical options or anatomy altering/restricting surgical procedures either did not work, or were not viable options. Earlier this year, the FDA approved a first-of-its-kind treatment that offers a neuroscience-based approach to the treatment of obesity, differentiating it from traditional weight loss surgical options.  As a member of the team that brought this new device through the clinical trial phase, I am pleased to have performed the first U.S. commercial implant of vBloc therapy. At Tufts Medical Center, we are committed to staying on the leading edge of new technologies that may benefit our patients,” Shah said in a press release.

St. Paul Minn.-based EnteroMedics won FDA approval for the device in January 2015, following a mixed vote last June after the device failed to meet its efficacy endpoint in a clinical trial.

“The 1st commercial implant of vBloc therapy marks another significant milestone for EnteroMedics and the millions of individuals with obesity who may be seeking different ways of achieving safe, effective weight loss. We are pleased with the response to vBloc therapy from patients and physicians alike and remain focused on the continued development of partnerships with bariatric centers of excellence and on driving reimbursement for vBloc therapy to ensure its widespread availability in the United States,” CEO Mark Knudson said in prepared remarks.

Filed Under: Neuromodulation/Neurostimulation, News Well, Weight loss Tagged With: Bariatrics, EnteroMedics Inc.

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy